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adOBJECTIVES The purpose of this study was to explore potential mediators of the effects of canagliflozin on heart failure
in the CANVAS Program (CANagliflozin cardioVascular Assessment Study; NCT01032629 and CANagliflozin cardioVascular
Assessment Study–Renal; NCT01989754).
BACKGROUND Canagliflozin reduced the risk of heart failure among patients with type 2 diabetes in the CANVAS
Program. The mechanism of protection is uncertain.
METHODS The percentages of mediating effects of 19 biomarkers were determined by comparing the hazard ratios for the
effect of randomized treatment from an unadjusted model and from a model adjusting for the biomarker of interest. Multi-
variable analyses were used to assess the joint effects of biomarkers that mediated most strongly in univariable analyses.
RESULTS Early changes after randomization in levels of 3 biomarkers (urinary albumin:creatinine ratio, serum
bicarbonate, and serum urate) were identified as mediating the effect of canagliflozin on heart failure. Average
post-randomization levels of 14 biomarkers (systolic blood pressure, low-density lipoprotein and high-density lipoprotein
cholesterol, total cholesterol, urinary albumin:creatinine ratio, weight, body mass index, gamma glutamyltransferase,
hematocrit, hemoglobin concentration, serum albumin, erythrocyte concentration, serum bicarbonate, and serum urate)
were identified as significant mediators. Individually, the 3 biomarkers with the largest mediating effect were erythrocyte
concentration (45%), hemoglobin concentration (43%), and serum urate (40%). In a parsimonious multivariable model,
erythrocyte concentration, serum urate, and urinary albumin:creatinine ratio were the 3 biomarkers that maximized
cumulative mediation (102%).
CONCLUSIONS A diverse set of potential mediators of the effect of canagliflozin on heart failure were identified. Some
mediating effects were anticipated, whereas others were not. The mediators that were identified support existing and
novel hypothesized mechanisms for the prevention of heart failure with sodium glucose cotransporter 2 inhibitors.
(J Am Coll Cardiol HF 2020;8:57–66) © 2020 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).N 2213-1779 https://doi.org/10.1016/j.jchf.2019.08.004
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lipoprotein cholesterol
MDRD = Modification of Diet in
Renal Disease
NHE3 = sodium hydrogen
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58SEE PAGE 67L arge-scale trials of sodium glucosecotransporter 2 (SGLT2) inhibitorshave shown marked reductions in
the risk of heart failure (1). In the CANVAS
Program (CANagliflozin cardioVascular
Assessment Study; NCT01032629 and CANa-
gliflozin cardioVascular Assessment Study–
Renal; NCT01989754), the hazard ratio (HR)
for hospitalized heart failure was 0.67
(95% confidence interval [CI]: 0.52 to 0.87),
in which effects appear early and are sus-
tained during follow-up (2). The primary ac-
tion of SGLT2 inhibitors is to prevent the
kidneys from reabsorbing glucose (3), which
results in improved glycemia, weight loss,
lowered blood pressure, and reduced excre-
tion of protein from the kidney (4). There
are other effects, including natriuresis and re-
ductions in body fluid volume, that may have
early and sustained effects on the risk of heart
failure (5).
To qualify as a potential mediator, a
biomarker must be both affected by the
drug under investigation and associated
with the outcome of interest. However, all
biomarkers that meet these criteria are not
necessarily mediators of the effect of thedrug because the criteria could also be seen for
biomarkers that lie outside the mechanistic pathway
(6). The investigation of mediators is further
complicated by the potential for confounding of as-
sociations, interactions between mediators, different
levels of precision with which potential mediatorsIngelheim, Durect, Eli Lilly, Gilead, GlaxoSmithKline, Janssen,
etrophin, Roche, Sanofi, Servier, and Vitae. Dr. Figtree has recei
ealth and Medical Research Council and Heart Foundation fellow
ion from Janssen for serving on the adjudication panel of the
for AbbVie, Astellas, AstraZeneca, Boehringer Ingelheim, Fresen
ceived research support from AbbVie, AstraZeneca, Boehringer
ants/contracts from Afferent, Amgen, Apple, Inc., AstraZeneca, Ca
Johnson, Luitpold, Medtronic, Merck, National Institutes of Heal
as a consultant for Abbott, Ablynx, AstraZeneca, Baim Insti
Kline, Johnson & Johnson, Medscape, Mitsubishi, Myokardia,
, SmartMedics, Springer Publishing, and University of California,
ards and/or as a speaker for Bayer, Boehringer Ingelheim, Fresen
steering committees for AbbVie and Janssen; and has served on
ysse and Shaw are employees of Janssen Research & Developmen
d has served on advisory boards and as a consultant for Novo Nor
en lectures for Novo Nordisk, Servier, Sanofi, Eli Lilly, Novartis,
tly serves as president of the European Association for the Study
m the Australian National Health and Medical Research Counc
ards and/or as a consultant for Janssen and Merck Sharpe & Dohm
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received May 1, 2019; revised manuscript received July 24, 2019can be recorded, different ways in which drug
effects on mediators can be measured, and the
choice of other covariates to be included in the
models (7).
A recent mediation analysis of the effects of the
SGLT2 inhibitor empagliflozin suggested that markers
of plasma volume were the most important mediator
for effects on cardiovascular mortality, but possible
mediating effects were also identified for fasting
plasma glucose (FPG), urinary albumin:creatinine ra-
tio (UACR), and uric acid (8). Some mediators that
might have been anticipated to be important, such as
blood pressure lowering, were not found to contribute
to the observed benefit. By contrast, others that might
not have been anticipated to be strong mediators of
protection against cardiovascular death, such as he-
moglobin, had apparently large effects.
The goal of the present analyses was to explore
potential mediators of the beneficial effects of cana-
gliflozin on heart failure in the CANVAS Program.METHODS
The CANVAS Program integrated data from 2 ran-
domized trials comparing the effects of canagliflozin
with those of placebo. All participants provided
written informed consent, and the trials were
registered.
PARTICIPANTS. Participants were individuals with
type 2 diabetes and an elevated cardiovascular risk
(2). Patients were either 30 years of age or older with aMerck, Novartis, Novo Nordisk, Pfizer, Pharmalink,
ved research support from the cofunded Australian
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TABLE 1 Effects of Canagliflozin on Biomarkers That May Mediate the Effect of Canagliflozin on Heart Failure
Mean  SE at Baseline Difference  SE at Follow-Up*
Placebo Canagliflozin Early Average
Glycemia
HbA1c, % 8.25  0.01 8.25  0.01 L0.62 ± 0.02 L0.52 ± 0.02
Vascular tone
SBP, mm Hg 136.90  0.24 136.44  0.21 L3.58 ± 0.26 L3.91 ± 0.19
DBP, mm Hg 77.81  0.15 77.62  0.13 L1.52 ± 0.15 L1.33 ± 0.11
Pulse rate, beats/min 72.49  0.16 72.64  0.14 0.06  0.16 0.22  0.12
Lipids, mmol/l
LDL-C† 2.30  0.01 2.29  0.01 0.09 ± 0.01 0.11 ± 0.01
HDL-C† 1.18  0.005 1.18  0.004 0.04 ± 0.004 0.05 ± 0.003
TG† 2.03  0.02 2.02  0.02 L0.06 ± 0.02 0.02  0.02
TC† 4.37  0.02 4.35  0.02 0.11 ± 0.02 0.16 ± 0.01
Renal
UACR, mg/g 20.49 (315.41)‡ 19.87 (288.54)‡ 0.83 (0.81, 0.85)§ 0.81 (0.79, 0.83)§
eGFR, ml/min/1.73 m2 76.18  0.32 76.68  0.27 L2.77 ± 0.22 L0.66 ± 0.19
Adiposity
Weight, kg 90.01  0.31 90.28  0.27 L1.33 ± 0.04 L2.20 ± 0.07
BMI, kg/m2 31.97  0.09 31.95  0.08 L0.47 ± 0.02 L0.79 ± 0.02
GGT, U/l 37.74  0.64 38.37  0.58 L3.89 ± 0.50 L4.34 ± 0.57
Volume status and hematopoiesis
Hematocrit, % 41.96  0.06 42.00  0.05 2.34 ± 0.07 2.53 ± 0.05
Hemoglobin, g/l 139.09  0.22 139.54  0.19 6.63 ± 0.22 7.65 ± 0.18
Serum albumin, g/l 41.40  0.05 41.32  0.04 0.59 ± 0.04 0.56 ± 0.04
Erythrocytes, 1012 cells/l 4.68  0.01 4.71  0.01 0.26 ± 0.01 0.27 ± 0.01
Indicators of acidosis/alkalosis
Serum bicarbonate, mmol/l 23.37  0.04 23.33  0.03 L0.42 ± 0.05 L0.34 ± 0.03
Other
Serum urate, mmol/l 349.78  1.47 348.21  1.24 L23.21 ± 1.16 L23.49 ± 1.02
Values in bold indicate significant effect at p < 0.05. *Mixed-model repeated-measures analysis using all data available before completion in patients who had baseline and
follow-up measurement for the respective outcome. The model adjusted for region, baseline HbA1c, eGFR, BMI, baseline of the outcome, treatment, visit, and study subgroup
(CANVAS or CANVAS-R). †Fasting test results. ‡Baseline data are geometric means (geometric coefficients of variation). §Differences are adjusted geometric mean ratio
(95% CI) obtained from the mixed-model with repeated-measures analysis applied on log-transformed data.
BMI ¼ body mass index; CI ¼ confidence interval; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular filtration rate; FPG ¼ fasting plasma glucose; GGT ¼ gamma
glutamyltransferase; HbA1c ¼ hemoglobin A1c; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; MDRD ¼ Modification of Diet in
Renal Disease; SBP ¼ systolic blood pressure; TC ¼ total cholesterol; TG ¼ triglyceride; UACR ¼ urinary albumin:creatinine ratio.
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59history of symptomatic atherosclerotic cardiovascular
disease or were 50 years of age or older with 2 or more
risk factors for cardiovascular disease. Participants
were required to have an estimated glomerular
filtration rate (eGFR) at entry of more than 30 ml/
min/1.73 m2 of body surface area.
RANDOMIZATION AND STUDY TREATMENT. After a
2-week, single-blind, placebo run-in period, partici-
pants were randomized to canagliflozin or to match-
ing placebo. Participants and all study staff were
masked to individual treatment allocations until
completion of the study.
FOLLOW-UP. Participants were followed and ran-
domized by face-to-face follow-up with 3 visits
scheduled in the first year and further visits
scheduled at 6-month intervals thereafter, with
alternating telephone follow-up and face-to-face
assessments. The occurrence of hospitalization forheart failure was evaluated at every scheduled
follow-up.
OUTCOMES. The outcome studied in this analysis
was the first hospitalized heart failure event during
follow-up. An endpoint adjudication committee
adjudicated all potential heart failure outcomes by
using rigorous definitions that were pre-specified
according to established criteria (9,10).
SELECTION OF POTENTIAL MEDIATORS. A diverse
set of biomarkers was measured at baseline and at
multiple time points during follow-up. The mediators
considered for investigation in this analysis were
identified through a process of consultation among
the investigator group, with selection based upon
insights derived from prior mediation analyses (8)
and known mechanisms underpinning SGLT2 inhibi-
tion and heart failure. Biomarker choice was also
dependent upon availability of data for assessment,
CENTRAL ILLUSTRATION Selection of Possible Mediators and Criteria for Mediation
Possible mediators of interest
(19 of the 22 biomarkers identified
met the mediation criteria)
Effects of canagliflozin
compared to placebo on
potential mediators





levels of potential mediators with
risk of heart failure
To be eligible as a mediator,
post-randomization biomarker
levels must be associated with









Biomarkers considered as potential mediators (n = 22)
Glycemia - HbA1c, FPG
Vascular tone - SBP, DBP, pulse rate
Lipids - LDL-C, HDL-C, TG, TC
Renal function - eGFR, UACR
Adiposity - weight, BMI, GGT
Volume status and hematopoiesis - hematocrit, hemoglobin,
serum albumin, erythrocytes
Indicators of acidosis/alkalosis - urine pH, ketonuria,
serum bicarbonate
Others - serum urate
Biomarkers meeting mediation criteria (n = 19)
Glycemia - HbA1c, FPG
Vascular tone - SBP, DBP
Lipids - LDL-C, HDL-C, TC
Renal function - eGFR, UACR
Adiposity - weight, BMI, GGT
Volume status and hematopoiesis - hematocrit, hemoglobin,
serum albumin, erythrocytes
Indicators of acidosis/alkalosis - urine pH, serum bicarbonate
Others - serum urate
Outcome of interest
(heart failure)
Li, J. et al. J Am Coll Cardiol HF. 2020;8(1):57–66.
To be eligible as a mediator, it was necessary for there to be, first, an effect of canagliflozin compared to placebo on the potential mediator and, second, an association
of post-randomization levels of the potential mediator with the risk of heart failure. A total of 22 biomarkers were considered potential mediators, and of these, 19
met the mediation criteria. BMI ¼ body mass index; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular filtration rate; FPG ¼ fasting plasma glucose;
GGT ¼ gamma glutamyltransferase; HbA1c ¼ hemoglobin A1c; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol;
SBP ¼ systolic blood pressure; TC ¼ total cholesterol; TG ¼ triglyceride; UACR ¼ urinary albumin:creatinine ratio.
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60and the absence of assays of B-type natriuretic pep-
tide within the CANVAS Program dataset was noted as
a significant shortcoming. Biomarkers that were
believed unlikely to be changed by treatment with
canagliflozin and unlikely to be associated with the
risk of heart failure were excluded. Potential media-
tors were grouped into those likely acting through
effects on glycemia, vascular tone, lipids, renal
function, adiposity, volume status or hematopoiesis,
acid-base balance, and serum urate (Table 1). FPG,
urine pH, and ketonuria were measured in CANVAS
but not in CANVAS-R (CANagliflozin cardioVascular
Assessment Study-Renal; NCT01989754) and were
assessed in subsidiary analyses restricted to CANVAS
participants. Ketonuria was assessed as a dichoto-
mous variable (none vs. trace or more), but all other
potential mediators were assessed as contin-
uous measurements.STATISTICAL ANALYSIS. For the mediator to be
eligible, it was necessary for there to be, first, an ef-
fect of canagliflozin compared to placebo on the po-
tential mediator, and second, an association between
post-randomization levels of the potential mediator
and the risk of heart failure (Central Illustration). For
the selection of potential mediators, the effects of
canagliflozin versus placebo on the potential medi-
ator were determined separately for each by using
mixed models incorporating repeated measures of
the variable of interest. The differences between
groups were assessed by using residual restricted
maximum likelihood tests. The exception to this
approach was for the evaluation of ketonuria in
CANVAS, which was assessed using a logistic regres-
sion model. Associations of the potential mediator
with heart failure were determined from Cox regres-
sion models.
J A C C : H E A R T F A I L U R E V O L . 8 , N O . 1 , 2 0 2 0 Li et al.
J A N U A R Y 2 0 2 0 : 5 7 – 6 6 Mediators of HF Effects With Canagliflozin
61There were 2 ways by which the effects of the
potential mediators were explored, reflecting prior
work suggesting that both early (11) and later (12)
effects of drugs on biomarkers may be important.
Early change was determined by estimating, for every
individual taking canagliflozin or placebo, the change
in the potential mediator from baseline to the first
post-randomization measurement, which was made
at various time points between 6 and 18 weeks into
follow-up. Average follow-up level was determined,
for every individual taking canagliflozin or placebo,
for all available measurements of the variable by
using time-dependent analysis. Eligible measure-
ments were those made at baseline and all mea-
surements made prior to the first hospitalization for a
heart failure event or prior to final follow-up for
those who did not experience an event.
Variables with skewed distributions were analyzed
after being log transformed (triglycerides [TG], UACR,
and gamma glutamyltransferase [GGT]). FPG, urine
pH, and ketonuria were available only from CANVAS.
Individuals without a baseline measurement of the
mediator of interest were excluded from the relevant
analyses, as were individuals with no follow-up
measurements and those with a baseline measure-
ment who were hospitalized for heart failure before a
follow-up measurement was made.
Primary analyses consisted of comparisons of HRs,
from Cox survival models, for the association be-
tween randomized treatment and the risk of heart
failure, unadjusted and adjusted for each biomarker,
in turn. In each case, the percentage mediation was






where HRc is the hazard ratio after adjustment for the
biomarker and HR is the unadjusted hazard ratio (13).
The 95% CIs for the estimated percentage of media-
tion were obtained using a 10,000-iteration bootstrap
resampling procedure. The combined potential
mediating effect of multiple biomarkers was quanti-
fied using the same equation. Multiple mediator
models were built by, first, selecting the biomarker
with the largest percentage of mediation value. Each
remaining biomarker was then included in turn, and
the next biomarker that produced the greatest joint
mediation was added to the existing model. This was
repeated until the mediation effect reached 100% in
the multivariable model. Only 1 variable from each
biomarker group was included in the multivariable
analysis because the goal was to capture different
mechanistic processes likely to mediate the effects of
the drug.
To further test the robustness of the findings, a
secondary analysis was performed using the productmethod under the counterfactual framework
approach (14) for univariable assessments and by
using nonlinear models (multiple additive regression
trees and smoothing splines) for multivariable as-
sessments, which are able to account for the collin-
earity between potential mediators (15).
For every analytic approach evaluating the medi-
ating effects of early change, the baseline level of the
biomarkers was adjusted to control for regression to
the mean. For the models assessing average effects,
this was unnecessary because the baseline value
already contributed to the calculation. All analyses
were performed using SAS version 9.4 (Cary, North
Carolina) and R studio version 1.1.463 (R Project,
Vienna, Austria). The p values < 0.05 were deemed
significant.
RESULTS
The potential mediating effects of 22 biomarkers were
assessed, 19 of which were available for the entire
CANVAS Program and 3 of which were available for
participants in CANVAS but not CANVAS-R. The time
to first measurement for the assessment of early
biomarker changes was #13 weeks for 12 biomarkers,
12 to 26 weeks for 5 biomarkers, and 18 to 52 weeks for
5 biomarkers. For the assessments of average
biomarker levels, the mean number of measurements
made was least for hematocrit, hemoglobin, erythro-
cytes, urine pH, and ketones (mean 8 measurement
times during follow-up) and most for blood pressure,
pulse rate, weight, and body mass index (BMI) (mean
19 measurements during follow-up). The overall
average number of biomarker measurements was 14.
EFFECTS OF CANAGLIFLOZIN COMPARED TO PLACEBO
ON POTENTIAL MEDIATORS. There were clear effects of
canagliflozin compared to placebo on multiple po-
tential mediators of effect (Central Illustration,
Table 1, Online Table 1). For example, hemoglobin A1c
(HbA1c), FPG, systolic blood pressure (SBP), diastolic
blood pressure (DBP), weight, BMI, urine pH, serum
bicarbonate, serum urate, serum GGT, low-density
lipoprotein cholesterol (LDL-C), high-density lipo-
protein cholesterol (HDL-C), total cholesterol (TC),
TG, hematocrit, hemoglobin, erythrocyte concentra-
tion, serum albumin, ketonuria, UACR, and eGFR.
ASSOCIATIONS OF POST-RANDOMIZATION LEVELS
OF POTENTIAL MEDIATORS WITH RISK OF HEART
FAILURE. For 14 of the 19 potential mediators (not
SBP, pulse rate, HDL-C, TG, or eGFR) assessed in the
overall CANVAS Program, there was a significant as-
sociation between the early change in levels and the
risk of heart failure in the regression models (p < 0.05)
TABLE 2 Observational Associations With Hospitalized Heart Failure of
Potential Mediators of the Effects of Canagliflozin When Represented as
Changes Measured Early After Randomization and as Average Levels During
Follow-Up
Early Change* Average Level*
Hazard Ratio
(95% CI) p Value
Hazard Ratio
(95% CI) p Value
Glycemia
HbA1c 1.23 (1.06–1.42) 0.007 1.08 (0.97–1.20) 0.161
Vascular tone
SBP 1.00 (0.99–1.01) 0.799 1.01 (1.01–1.02) 0.002
DBP 0.98 (0.96–0.99) 0.009 0.98 (0.97–0.99) 0.004
Pulse rate 1.00 (0.98–1.02) 0.879 1.02 (1.01–1.03) <0.001
Lipids
LDL-C 0.79 (0.63–0.99) 0.037 0.78 (0.67–0.91) 0.002
HDL-C 0.60 (0.26–1.37) 0.225 0.41 (0.26–0.66) <0.001
TG 0.75 (0.50–1.13) 0.169 0.99 (0.76–1.29) 0.951
TC 0.80 (0.66–0.96) 0.019 0.82 (0.72–0.93) 0.002
Renal
UACR 1.36 (1.14–1.61) 0.001 1.50 (1.40–1.61) <0.001
eGFR (MDRD) 0.99 (0.97–1.00) 0.056 0.98 (0.97–0.98) <0.001
Adiposity
Weight 1.08 (1.02–1.14) 0.009 1.02 (1.02–1.03) <0.001
BMI 1.26 (1.06–1.48) 0.007 1.09 (1.07–1.11) <0.001
GGT 1.60 (1.07–2.38) 0.022 1.95 (1.68–2.27) <0.001
Volume status and hematopoiesis
Hematocrit 0.93 (0.88–0.97) 0.001 0.94 (0.91–0.97) <0.001
Hemoglobin 0.97 (0.96–0.99) <0.001 0.98 (0.97–0.99) <0.001
Albumin 0.92 (0.87–0.98) 0.006 0.82 (0.79–0.84) <0.001
Erythrocytes 0.58 (0.37–0.92) 0.020 0.57 (0.43–0.75) <0.001
Indicators of acidosis/alkalosis
Serum bicarbonate 1.11 (1.05–1.18) <0.001 1.10 (1.05–1.16) <0.001
Other
Serum urate 1.00 (1.00–1.01) <0.001 1.01 (1.00–1.01) <0.001
Values in bold indicate significant effect at p <0.05. *Values are the effect of a 1-unit post-
randomization increase.
Abbreviations as in Table 1.
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62(Table 2). For the average post-randomization levels,
there were significant associations observed for 17 of
the 19 biomarkers (not HbA1c or TG). The supplemen-
tary analyses of the biomarkers measured only in
CANVAS identified additional significant associations
between both the early change and average follow-up
levels with the risk of heart failure for FPG and urine
pH (Online Table 2).
ESTIMATED MEDIATION OF THE EFFECTS OF
CANAGLIFLOZIN ON HEART FAILURE. There were 16
biomarkers (2 in CANVAS alone) for which early
changes in post-randomization levels were achieved
with canagliflozin versus placebo and for which those
early changes in biomarker levels were also associated
with the subsequent risk of heart failure (all except for
SBP, pulse rate, HDL-C, TG, eGFR, and ketonuria). Just
3 of these 16 biomarkers (UACR, serum bicarbonate,and serum urate) were identified as individually sta-
tistically significant mediators of the effect of cana-
gliflozin on heart failure, when the early changes in
biomarker levels were assessed in the primary models
(Table 3, Online Table 3). Assessment of joint effects of
mediators representing different modes of action
included hemoglobin, serum urate, and HbA1c as the
set of 3 that produced the largest combined percentage
of mediation with an estimated cumulative mediation
of 110% (95% CI: –379 to 877) of the effects of cana-
gliflozin on heart failure (Table 4).
There were 17 biomarkers for which average post-
randomization levels were modified with canagli-
flozin versus placebo and for which those early
changes in biomarker levels were also associated with
the subsequent risk of heart failure (SBP, DBP, TC,
LDL-C, HDL-C, UACR, eGFR, weight, BMI, hematocrit,
hemoglobin, serum albumin, erythrocytes, serum bi-
carbonate, serum urate, GGT, and urine pH). Fourteen
of these biomarkers were identified as individually
significant mediators of the effect of canagliflozin on
heart failure, when the average post-randomization
levels were assessed in the primary models. The 3
biomarkers with the largest magnitude of mediating
effect were erythrocyte concentration, hemoglobin,
and serum urate concentration (Table 3). Assessment
of joint effects in a multivariable model of the stron-
gest 3 mediators representing different modes of ac-
tion resulted in the inclusion of erythrocyte
concentration, serum urate, and UACR and an esti-
mated cumulative mediation of 102% (95% CI: 42 to
480) of the effects of canagliflozin on heart failure
(Table 4). Estimates were not substantively different if
alternative biomarkers from the volume and hemato-
poiesis group (erythrocyte concentration, hematocrit,
or serum albumin) were substituted for hemoglobin
concentration (Online Table 4).
Subsidiary analyses based upon the alternative
counterfactual framework identified 11 mediators
based upon early changes in biomarker levels and
13 mediators based upon average levels. In the multi-
variable model, assessment of the early changes in
hemoglobin, serum urate, and HbA1c provided a value
for the estimated overall mediation of 75% (95% CI:
47 to 101). For the corresponding model assessing
average levels of biomarkers the inclusion of eryth-
rocyte concentration, serum urate and UACR resulted
in an estimated overall mediation of 94% (95% CI:
85 to 103).
DISCUSSION
The key methods and findings of this study are
summarized in Table 5. A large set of potential
TABLE 3 Individual Assessments of Potential Mediators of the Effect of Canagliflozin on Heart Failure When Represented as Changes Measured Early After
Randomization and as Average Levels During Follow-Up
Early Change Average Level
Events/Patients Hazard Ratio (95% CI) % Mediation (95% CI) Events/Patients Hazard Ratio (95% CI) % Mediation (95% CI)
Unadjusted Hazard Ratio 0.67 (0.52–0.87) 0.67 (0.52–0.87)
Adjusted for glycemia
HbA1c 218/9,854 0.77 (0.57 to 1.03) 23.0 (8.30 to 111) – – –
Adjusted for vascular tone
SBP – – – 223/9,988 0.75 (0.57 to 0.98) 11.8 (3.23 to 41.3)*
DBP 223/9,985 0.68 (0.52 to 0.89) 12.6 (61.0 to 2.55) 223/9,988 0.70 (0.53 to 0.91) 7.21 (23.1 to 2.52)†
Pulse rate – – – – – –
Adjusted for lipids
LDL-C 198/9,436 0.75 (0.56 to 0.99) 4.39 (2.86 to 31.1) 202/9,671 0.75 (0.56 to 0.99) 6.02 (1.91 to 26.2)*
HDL-C – – – 202/9,674 0.76 (0.57 to 1.00) 9.29 (3.56 to 40.8)*
Triglycerides – – – – – –
TC 198/9,440 0.75 (0.56 to 1.00) 5.26 (1.98 to 38.6) 202/9,675 0.75 (0.57 to 1.00) 7.65 (2.13 to 33.0)*
Adjusted for renal effects
UACR 204/9,533 0.76 (0.58 to 1.01) 20.4 (3.74 to 93.7)* 206/9,637 0.79 (0.60 to 1.05) 29.8 (13.5 to 100)*
eGFR (MDRD) – – – 223/9,975 0.71 (0.54 to 0.92) 3.06 (14.1 to 1.17)
Adjusted for adiposity
Weight 223/9,977 0.77 (0.58 to 1.02) 18.9 (14.0 to 133) 223/9,983 0.75 (0.57 to 0.98) 11.2 (4.81 to 35.2)*
BMI 222/9,964 0.77 (0.58 to 1.02) 21.0 (11.3 to 118) 222/9,970 0.76 (0.58 to 1.00) 17.8 (8.29 to 53.1)*
GGT 223/9,967 0.75 (0.57 to 0.98) 11.7 (2.43 to 59.9) 223/9,975 0.77 (0.59 to 1.01) 20.4 (10.0 to 63.0)*
Adjusted for volume status and hematopoiesis
Hematocrit 170/9,014 0.85 (0.61 to 1.18) 45.7 (12.5 to 320) 173/9,424 0.83 (0.60 to 1.13) 39.6 (9.86 to 153)*
Hemoglobin 173/9,106 0.88 (0.64 to 1.21) 52.1 (150 to 449) 176/9,477 0.85 (0.63 to 1.16) 43.4 (12.4 to 206)*
Serum albumin 223/9,967 0.74 (0.57 to 0.97) 9.84 (9.10 to 58.9) 223/9,975 0.82 (0.63 to 1.07) 36.2 (17.9 to 112)*
Erythrocytes 173/9,106 0.85 (0.61 to 1.18) 39.4 (101 to 362) 176/9,477 0.86 (0.63 to 1.17) 45.1 (10.9 to 226)*
Adjusted for acidosis/alkalosis
Serum bicarbonate 223/9,964 0.74 (0.57 to 0.97) 9.49 (1.16 to 43.1)* 223/9,972 0.74 (0.56 to 0.96) 7.06 (2.83 to 23.1)*
Adjusted for others
Serum urate 223/9,967 0.79 (0.60 to 1.04) 27.0 (6.61 to 128)* 223/9,975 0.83 (0.63 to 1.08) 39.7 (20.5 to 122)*
Ten thousand bootstrap iterations were used to calculate 95% CI for percent mediation. *Potential mediators based on significant (p < 0.05) effects of canagliflozin on the biomarker and significant
(p < 0.05) associations of the biomarker with the future risk of heart failure, together with evidence of significant mediation. †DBP was shown to have a negative mediating effect on heart failure.
Abbreviations as in Table 1.
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63mediators of the effect of canagliflozin on heart fail-
ure was identified. Some of the mediators, such as
markers of plasma volume, are highly plausible based
upon the known causes of heart failure (16). Others,
such as SBP, were not identified as strong or consis-
tent mediators despite long-established effects of
blood pressure–lowering agents on heart failure and
clear effects of canagliflozin on blood pressure (17).
Others still, such as blood lipid levels, were identified
as weak mediators but with no known mechanism of
action. The most consistent finding across all the
analyses was of strong mediating effects for the
markers of volume and hematopoiesis and for medi-
ating effects of uric acid. Mediating effects for albu-
minuria in many of the models highlights a likely
central role for the cardiorenal axis in mediating the
effects of canagliflozin on heart failure.
Volume reduction would be anticipated to mediate
the prevention of heart failure primarily by reducingpreload (16). Observed mediating effects of adiposity
are also likely, partly at least because they reflect vol-
ume effects with early reductions in weight, probably
due to fluid loss, whereas later incremental weight loss
probably indicates reduction in fat mass (5). Effects of
canagliflozin on GGT were included as an indicator of
adiposity effects because changes in GGT are likely to
be due to reductions in hepatic steatosis (18,19).
In addition to signaling diuresis and a decrease in
plasma volume, effects of SGLT2 inhibition on serum
hemoglobin, erythrocytes, hematocrit, and serum al-
bumin could also indicate changes in red cell mass
due to an effect on erythropoiesis (20). Dapagliflozin
therapy has been reported to raise levels of erythro-
poietin soon after it is initiated, with increases in
reticulocyte count noted prior to subsequent eleva-
tion of hemoglobin and hematocrit (21). Enhanced
delivery of oxygen to the tissues has been postulated
as a mechanism for the benefits of SGLT2 inhibition
TABLE 4 Joint Assessments of Potential Mediators of the Effect of Canagliflozin on Heart Failure When Fitted as Changes Measured Early After
Randomization and as Average Levels During Follow-Up










Unadjusted Hazard Ratio 0.67 (0.52–0.87) 0.67 (0.52–0.87)
Adjusted for
Hemoglobin 173/9,106 0.88 (0.64 to 1.21) 52.1 (150 to 449) Erythrocytes 176/9,477 0.86 (0.63 to 1.17) 45.1 (10.9 to 226.0)
þ Serum urate 173/9,104 0.97 (0.71 to 1.34) 89.4 (358 to 733) þ Serum urate 176/9,475 0.96 (0.70 to 1.31) 84.6 (36.5 to 356.0)
þ HbA1c 173/9,104 1.03 (0.73 to 1.45) 110 (379 to 877) þ UACR 173/9,264 1.01 (0.73 to 1.38) 102 (42.1 to 480.0)
Abbreviations as in Table 1.
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64on kidney disease (20), and parallel mechanisms may
also avert hypoxia in the heart (22).
Reduction in albuminuria with SGLT2 inhibition is
believed to be jointly attributable to changes in the
glomerular filtering of albumin and increased tubular
reabsorption. Favorable effects on endothelial func-
tion, which improve endothelial glycocalyx barrier
function in the kidney, have been postulated, and
parallel benefits in other vascular beds may explain
improvements in cardiac function (23,24).
The lowering of uric acid achieved with SGLT2 in-
hibitor treatment is believed to result from enhanced
urinary excretion (25). Elevated serum urate levels
have been associated with heart failure and other
vascular diseases in prior studies (26), but there is no
clear understanding of how uric acid lowering due to
SGLT2 inhibition would drive reduction in heart fail-
ure risk.
Little evidence was found for effects on glycemia
mediating the impact of canagliflozin on heart failure,
although the only moderate effects of canagliflozin on
glycemia and the absence of systematic assessments
of plasma glucose during follow-up may have miti-
gated against the detection of effects.
It has been hypothesized that, under persistent
mild ketosis caused by SGLT2 inhibition (27), thereTABLE 5 Key Methods and Findings
Canagliflozin reduced the risk of heart failure among patients with
type 2 diabetes in the CANVAS (CANagliflozin cardioVascular
Assessment Study) Program. The mechanism of protection was
explored by fitting univariable and multivariable models to assess
mediation.
 Biomarkers were selected for investigation based upon avail-
ability and agreement among the investigator team members.
 Assessment for mediation was done only for biomarkers that
were changed by canagliflozin and associated with
heart failure.
 Markers of volume were the strongest mediators of risk fol-
lowed by serum urate and urinary albumin:creatinine ratio.
 Subsidiary analyses were broadly consistent in the findings.
Identified mediators support existing and novel hypothesized
mechanisms for the prevention of heart failure with sodium
glucose cotransporter 2 (SGLT2) inhibitors.may be preferential uptake of b-hydroxybutyrate by
the myocardium and protection of the failing heart
(28). Imprecise measurement of ketonuria and data
collection restricted to the CANVAS trial alone
might have mitigated against detection of a medi-
ating effect of ketosis. The observed reduction in
bicarbonate and associated mediating effect may be
due to effects of canagliflozin on sodium hydrogen
exchanger-3 (NHE3) (16,29). Inhibition of SGLT2
down-regulates NHE3 and may mediate effects of
canagliflozin on heart failure through a natriuretic
effect (21).
SBP was identified as a weak and inconsistent
mediator of the effect of canagliflozin on heart failure
in these analyses, and DBP was consistently shown to
have a moderate-sized negative mediating effect.
There is no clear explanation for this latter observa-
tion, but the failure to detect a mediating effect for
SBP may be a consequence of the substantial within-
person variability of SBP, which reduces the capac-
ity to precisely define effects on SBP at an individual
level.
The EMPA-REG OUTCOME trial has previously
sought to understand the mechanism through which
empagliflozin protected against death from cardio-
vascular disease. Those analyses concluded that ef-
fects on plasma volume were the most important
mediators of effect but also highlighted the role of
changes in FPG, UACR, and uric acid (8). Although CIs
for estimates of mediating effects were not provided
in that report, there does appear to be some com-
monality of findings, albeit for a different clinical
outcome.
STUDY LIMITATIONS. These analyses of the
CANVAS Program benefited from the large size of
the dataset, the high quality of trial conduct, the
range of biomarkers available for analysis, the
robust adjudication of heart failure outcomes, and
the range of methods applied to assess mediation.
There were also multiple measurements available
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Sodium glucose
cotransporter 2 (SGLT2) inhibitors provide significant protection
against heart failure. This benefit was not anticipated when the
trials of these agents were initially designed. Mediation analyses
can provide insights into the mechanism by which drug effects
are achieved and may enable the better targeting of therapy to
patient groups most likely to benefit.
TRANSLATIONAL OUTLOOK 1: The statistical tools upon
which mediation analyses are based have significant limitations,
even when applied to very large datasets. Applying a breadth of
analytic approaches emphasizes the extent to which findings
depend upon the methodology selected and highlights the level
of persisting uncertainty.
TRANSLATIONAL OUTLOOK 2: Smaller, dedicated mecha-
nistic studies specifically designed to test the mediating effects
of individual candidate biomarkers may be a more effective way
of defining the mechanism by which SGLT2 inhibition prevents
heart failure.
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65for most potential mediators, and there was no
need for imputation of data. However, there were
also important limitations. All these investigations
were performed post hoc and required multiple
statistical tests, and the results are hypothesis-
generating in every case. Only the potential medi-
ating effects of biomarkers measured during the
trial were able to be assessed, and it was not
possible to directly assess the potential role of
B-type natriuretic peptide and pathways acting
through mechanisms such as inflammation (30),
oxidative stress (31), arterial stiffness, or vascular
resistance (32). Also, the authors were unable to
adjust for potential effects of competing risks.
There are significant challenges inherent in the
statistics underlying the methodologies with limited
capacity to control for interactions between media-
tors and provide robust estimates of uncertainty.
The findings were sensitive to whether the mediator
was explored in terms of the early effect or the
average effect, which may reflect the capacity of the
different methodologies to detect mediating effects,
as much as it does real differences in early versus
late mechanistic pathways. For example, assess-
ment of mediation based upon early changes after
follow-up are likely to be systematically under-
estimated compared to assessment of mediation
based upon average changes, because statistical
estimates based upon 1 or 2 measurements of a
biomarker are much less powerful than those based
upon multiple measures. Assessments of the joint
effects of mediators resulted in more than 100% of
the effect explained with only 3 mediators included,
and this highlights the limited capacity to explore
and control for double-counting of a mechanistic
pathway captured by more than 1 biomarker.
Finally, it is not possible to be sure that the effects
identified are truly part of the mechanistic pathway
for heart failure prevention by canagliflozin rather
than an epiphenomenon associated with both the
effects of canagliflozin and the future risk of
heart failure.
CONCLUSIONS
We identified a diverse set of potential mediators of
the effect of canagliflozin on heart failure. Somemediating effects were anticipated, and others were
not. These analyses provide support for most of
the previously hypothesized mechanisms for the
prevention of heart failure with SGLT2 inhibitors, but
the extent to which each marker truly mediates the
beneficial effect of canagliflozin on heart failure
remains uncertain.
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